

JOURNAL OF HEPATOLOGY

VOLUME 63, ISSUE 2, PAGES 293–536

FROM THE EDITOR'S DESK

From the Editor's desk – August 2015

R. Moreau, R. Batailler, T. Berg, J. Zucman-Rossi and R. Jalan 293

OBITUARY

Paul Angulo: Clinician investigator

J. George, E. Bugianesi, Journal of Hepatology Editorial Team 296

EDITORIALS

Liver disease in the UK: Startling findings & urgent need for action
R. Williams 297

Hepatitis C treatment and quality of life – You can't always get what you want, but you might get what you need
G. Mehta and G. Dusheiko 300

A new horizon for liver support in acute liver failure
N.A. Davies and R. Bañares 303

Sugar sweetened beverages and fatty liver disease: Rising concern and call to action
M.F. Abdelmalek and C. Day 306

Sarcopenia in non-alcoholic fatty liver disease: Targeting the real culprit?
M. Merli and S. Dasarathy 309

RESEARCH ARTICLES

Viral Hepatitis

Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity
A. Madejón, J. Sheldon, I. Francisco-Recuero, C. Perales, M. Domínguez-Beato, M. Lasa, I. Sánchez-Perez, J. Muntané, E. Domingo, J. García-Samaniego and A. Sánchez-Pacheco 312

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

E.J. Gane, Y.-S. Lim, S.C. Gordon, K. Visvanathan, E. Sicard, R.N. Fedorak, S. Roberts, B. Massetto, Z. Ye, S. Pflanz, K.L. Garrison, A. Gaggar, G. Mani Subramanian, J.G. McHutchison, S. Kottlilil, B. Freilich, C.S. Coffin, W. Cheng and Y.J. Kim 320

Liver-directed gene therapy of chronic hepatitis B virus infection using interferon alpha tethered to apolipoprotein A-I

P. Berraondo, M. Di Scala, K. Korolowicz, L.M. Thampi, I. Otano, L. Suarez, J. Fioravanti, F. Aranda, N. Ardaiz, J. Yang, B.V. Kallakury, R.D. Tucker, M. Vasquez, S. Menne, J. Prieto and G. González-Aseguinolaza 329

Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir
Z.M. Younossi, M. Stepanova, N. Afdhal, K.V. Kowdley, S. Zeuzem, L. Henry, S.L. Hunt and P. Marcellin 337

Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection

K. Giersch, L. Allweiss, T. Volz, M. Helbig, J. Bierwolf, A.W. Lohse, J.M. Pollok, J. Petersen, M. Dandri and M. Lütgehetmann 346

Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan

C.-L. Chen, J.-Y. Yang, S.-F. Lin, C.-A. Sun, C.-H. Bai, S.-L. You, C.-J. Chen, J.-H. Kao, P.-J. Chen and D.-S. Chen 354

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine

J. Lalezari, J.G. Sullivan, P. Varunok, E. Galen, K.V. Kowdley, V. Rustgi, H. Aguilar, F. Felizarta, B. McGovern, M. King, A.R. Polepally and D.E. Cohen 364

Liver Failure and Growth

The specificity and accuracy of ¹¹¹In-hexavalent lactoside in estimating liver reserve and its threshold value for mortality in mice

M.-H. Wang, C.-Y. Chien, P.-Y. Wang, H.-M. Yu, H.-S. Lee and W.-J. Lin 370

Efficacy of coupled low-volume plasma exchange with plasma filtration adsorption in treating pigs with acute liver failure: A randomised study

N. Zhou, J. Li, Y. Zhang, J. Lu, E. Chen, W. Du, J. Wang, X. Pan, D. Zhu, Y. Yang, Y. Chen, H. Cao and L. Li 378

Pivotal preclinical trial of the spheroid reservoir bioartificial liver

J.M. Glorioso, S.A. Mao, B. Rodysill, T. Mounajjed, W.K. Kremers, F. Elgilani, R.D. Hickey, H. Haugaa, C.F. Rose, B. Amiot and S.L. Nyberg 388

Cancer

Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia

Y. Mizuguchi, S. Specht, K. Isse, E. Sasatomi, J.G. Lunz 3rd, T. Takizawa and A.J. Demetris 399

MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer

H.J. Bae, K.H. Jung, J.W. Eun, Q. Shen, H.S. Kim, S.J. Park, W.C. Shin, H.D. Yang, W.S. Park, J.Y. Lee and S.W. Nam 408

Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic *kras* expression in transgenic zebrafish

C. Yan, X. Huo, S. Wang, Y. Feng and Z. Gong 420

Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features

D. Kopanja, A. Pandey, M. Kiefer, Z. Wang, N. Chandan, J.R. Carr, R. Franks, D.-Y. Yu, G. Guzman, A. Maker and P. Raychaudhuri 429

Molecular and Cell Biology

Fasting-induced G0/G1 switch gene 2 and FGF21 expression in the liver are under regulation of adipose tissue derived fatty acids

D. Jaeger, G. Schoiswohl, P. Hofer, R. Schreiber, M. Schweiger, T.O. Eichmann, N.M. Pollak, N. Poecher, G.F. Grabner, K.A. Zierler, S. Eder, D. Kolb, F.P.W. Radner, K. Preiss-Landl, A. Lass, R. Zechner, E.E. Kershaw and G. Haemmerle 437

Chronic replicative stress induced by CCl₄ in TRF1 knockout mice recapitulates the origin of large liver cell changes

F. Beier, P. Martinez and M.A. Blasco 446

Cholestasis and Autoimmune Diseases

Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study

E.A. Wikström Shemer, O. Stephansson, M. Thuresson, M. Thorsell, J.F. Ludvigsson and H.-U. Marschall 456

Genetic and Metabolic Diseases

Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts

J. Ma, C.S. Fox, P.F. Jacques, E.K. Speliotes, U. Hoffmann, C.E. Smith, E. Saltzman and N.M. McKeown 462

Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study

J.L. Mellinger, K.M. Pencina, J.M. Massaro, U. Hoffmann, S. Seshadri, C.S. Fox, C.J. O'Donnell and E.K. Speliotes 470

Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance

H.Y. Kim, S.Y. Park, M.H. Lee, J.H. Rho, Y.J. Oh, H.U. Jung, S.H. Yoo, N.Y. Jeong, H.J. Lee, S. Suh, S.Y. Seo, J. Cheong, J.S. Jeong and Y.H. Yoo 477

Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011)

Y.-h. Lee, K.S. Jung, S.U. Kim, H.-j. Yoon, Y.J. Yun, B.-W. Lee, E.S. Kang, K.-H. Han, H.C. Lee and B.-S. Cha 486

Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding *PNPLA3*, *SAMM50*, and *PARVB* of patients with non-alcoholic fatty liver disease

T. Kitamoto, A. Kitamoto, Y. Ogawa, Y. Honda, K. Imajo, S. Saito, M. Yoneda, T. Nakamura, A. Nakajima and K. Hotta 494

REVIEW

Drug-induced liver injury: Interactions between drug properties and host factors

M. Chen, A. Suzuki, J. Borlak, R.J. Andrade and M.I. Lucena 503

SPECIAL SECTIONS

Public Health

Immigration and viral hepatitis

S. Sharma, M. Carballo, J.J. Feld and H.L.A. Janssen 515

Hepatology Snapshot

Hepatic regenerative medicine

G. Mazza, P. De Coppi, P. Gissen and M. Pinzani 523

LETTERS TO THE EDITOR

An autosomal dominant form of non-cirrhotic portal hypertension

A. Majumdar, M.B. Delatycki, P. Crowley, J. Lokan, B. Tharian, P.W. Angus and P. Gow 525

Low ascitic fluid protein does not indicate an increased risk for spontaneous bacterial peritonitis in current cohorts

T. Bruns, P. Lutz, A. Stallmach and H.D. Nischalke 527

Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: An undesirable association?
S.A.d.S. Miozzo, C.V. Tovo, J.A. John and A.A. de Mattos 529

Evidence supporting a beneficial role of vitamin D in chronic hepatitis C
Q. Pang, K. Qu, J.-Y. Zhang and C. Liu 530

Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C"
M.T. Kitson, C. Sarrazin, P. Toniutto and S.K. Roberts 531

Hepatocyte senescence explains conjugated bilirubinaemia in chronic liver failure
A.D. Aravinthan and G.J.M. Alexander 532

Strain ultrasound elastography for liver diseases
Q.-C. Kan, X.-W. Cui, J.-M. Chang and C.F. Dietrich 534

Reply to: "Strain ultrasound elastography for liver diseases"
B.E. Van Beers 535

ERRATUM

Erratum to "Hepatic hepcidin expression is decreased in cirrhosis and HCC" [J Hepatol 2015;62:977–979]
S.M. Kessler, A. Barghash, S. Laggai, V. Helms and A.K. Kiemer 536

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases, Wikström Shemer *et al.* (pages 456–461) in this issue.